Pneumocystis Pneumonia Infection Following the Initiation of Pembrolizumab Therapy for Lung Adenocarcinoma.

MLA

Sumi, Toshiyuki, et al. “Pneumocystis Pneumonia Infection Following the Initiation of Pembrolizumab Therapy for Lung Adenocarcinoma.” Internal Medicine (Tokyo, Japan), vol. 62, no. 22, Nov. 2023, pp. 3381–85. EBSCOhost, https://doi.org/10.2169/internalmedicine.1163-22.

APA

Sumi, T., Takeda, K., Michimata, H., Nagayama, D., Koshino, Y., Watanabe, H., Yamada, Y., Kodama, K., Nishikiori, H., & Chiba, H. (2023). Pneumocystis Pneumonia Infection Following the Initiation of Pembrolizumab Therapy for Lung Adenocarcinoma. Internal Medicine (Tokyo, Japan), 62(22), 3381–3385. https://doi.org/10.2169/internalmedicine.1163-22

Chicago

Sumi, Toshiyuki, Kazuya Takeda, Haruhiko Michimata, Daiki Nagayama, Yuta Koshino, Hiroki Watanabe, Yuichi Yamada, Kentaro Kodama, Hirotaka Nishikiori, and Hirofumi Chiba. 2023. “Pneumocystis Pneumonia Infection Following the Initiation of Pembrolizumab Therapy for Lung Adenocarcinoma.” Internal Medicine (Tokyo, Japan) 62 (22): 3381–85. doi:10.2169/internalmedicine.1163-22.